Connect with us

Technology

TNL Mediagene Pursues Cost-Efficient Expansion with New C-Level Hires and Strategic M&A Focus

Published

on

NEW YORK and TOKYO, May 7, 2025 /PRNewswire/ — TNL Mediagene (Nasdaq: TNMG), a Tokyo-based next-generation digital media and data group in Asia, today announced its Strategic Expansion Plan comprising two pillars, Global Talent Management and Global Strategic M&A. The plan, spanning the next 24-month period, outlines the company’s focus on cost-efficient revenue growth, toward its goal of continued growth in revenue while further improving Adjusted EBITDA.

As part of its Global Talent Management pillar, the company announced the appointment of Aya Miyake as Chief Governance Officer and Carly Ma as Chief Human Resources Officer.

Aya Miyake brings over two decades of capital markets and business experience including executive roles at Tokyo Stock Exchange, Osaka Securities Exchange and Automotive Fund. Aya’s extensive experience includes corporate governance, public listings, capital raising, investor relations and compliance. Aya’s role as Chief Governance Officer at TNL Mediagene will strengthen the company’s expertise in public company matters and bolster its C-level oversight and control functions.

Carly Ma brings over a decade of HR experience at multinational corporations with roles at Porsche Taiwan Motors, a subsidiary of Porsche A.G. Germany, Amazon Fulfillment Services and Amazon Canada. Carly’s experience includes talent acquisition, talent optimization and corporate culture development programs. Carly’s experience at multinational companies will strengthen TNL Mediagene’s talent acquisition and talent optimization functions and align the company’s practices with best-practice international standards.

“Aya’s wealth of experience in the capital markets and adjacent areas will bolster our institutional knowledge in all areas of public company matters as well as enhance our C-level oversight and control functions. Carly’s experience in multinational corporate HR will bring HR best practices to our company, help us acquire and retain talent as well as optimize our talent pool going forward. We are thrilled to welcome them to the TNL Mediagene family” Co-Founder & CEO Joey Chung said.

As part of the Global Strategic M&A pillar, the company gave an update on its M&A strategy including its focus on enhancing revenue growth and revenue diversification via M&A. The company’s geographic focus areas for strategic expansion include the Southeast Asia, Japan and Taiwan markets where the company sees the highest ROI and synergy potential as well as English language markets such as the US, Canada, UK and Australia.

“M&A has been a part of our DNA for some time now. We have acquired and integrated 10 companies since 2018 and maintain an active pipeline of M&A opportunities. We have close relationships with our bankers and continue to actively screen targets with them. In the near-term we see opportunities in Southeast Asia, Japan and Taiwan and in the medium to longer-term we see opportunities in the US and other English language markets. Right now, we are most focused on assets that are complementary to our current businesses or assets where we can add value and enhance with our relative strengths in technology products, multilingualization or cost discipline. These can include, for example, assets with large regional audiences but less sophisticated tech, assets with a solid offering that we can expand into a new language market with our multilingualization strategies or assets where we can add value by taking cost out using our cost discipline strategies.”

TNL Mediagene believes M&A is a key component of its financial performance and intends to be acquisitive going forward.

“In FY2024 we achieved 35% revenue growth, a ~1% gross margin expansion to 36.6%, and a ~1% Adjusted EBITDA margin expansion to near break-even at -1.8%. We are proud of these results and believe they are a testament to our ability to grow our revenues while running our businesses in a cost-efficient manner. Strategic M&A has always been a part of that equation and we expect that to continue going forward” Joey concluded.

Summary Financials:

For the year ended December 31,

($ in dollars, unless otherwise stated)

2022

2023

2024

Revenue

20,009,994

35,838,780

48,493,897

Growth %

79.1 %

35.3 %

Gross Profit

7,741,196

12,651,384

17,738,557

Margin %

38.7 %

35.3 %

36.6 %

Adjusted EBITDA

-1,687,729

-998,162

-854,174

Margin %

-8.4 %

-2.8 %

-1.8 %

 

The condensed financial information presented in this press release should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2024 included in TNL Mediagene’s annual report on Form 20-F filed with the SEC on April 30, 2025, which provides a more complete discussion of its accounting policies and certain other information.

About TNL Mediagene

Headquartered in Tokyo, TNL Mediagene was formed in May 2023 through the merger of Taiwan’s The News Lens Co. and Japan’s Mediagene Inc., two of the region’s leading independent digital media groups. The company’s operations span original and licensed media brands in Japanese, Chinese, and English, covering topics such as news, business, technology, science, food, sports, and lifestyle. It also offers AI-driven advertising services, marketing technology platforms, e-commerce, and innovative solutions tailored to the needs of advertising agencies. Known for its political neutrality, appeal to younger audiences, and high-quality content, TNL Mediagene has approximately 500 employees across Asia, with offices in Japan, Taiwan, and Hong Kong.

https://www.tnlmediagene.com/

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on beliefs and assumptions and on information currently available to TNL Mediagene. Forward-looking statements generally relate to future events or TNL Mediagene’s future financial or operating performance. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements in this communication include, but are not limited to, statements in the section entitled “2025 Initiatives and Outlook” and “Management Commentary” such as statements about TNL Mediagene’s future business plan and growth strategies and statements by TNL Mediagene’s CEO and president. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including strategies or plans, are also forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for TNL Mediagene to predict these events or how they may affect TNL Mediagene. In addition, risks and uncertainties are described in TNL Mediagene’s filings with the Securities and Exchange Commission. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. TNL Mediagene cannot assure you that the forward-looking statements in this communication will prove to be accurate. There may be additional risks that TNL Mediagene presently does not know or that TNL Mediagene currently does not believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by TNL Mediagene, its directors, officers or employees or any other person. Except as required by applicable law, TNL Mediagene does not have any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date of this communication. You should, therefore, not rely on these forward-looking statements as representing the views of TNL Mediagene as of any date subsequent to the date of this communication.

Use of Non-IFRS Financial Measures
In this press release we have included adjusted EBITDA, a non-IFRS financial measure, which is a key measure used by our management and board of directors in evaluating our operating performance.

Adjusted EBITDA is our preferred metric for profitability because we believe it facilitates operating performance comparisons on a period-to-period basis and excludes items that we do not consider to be indicative of our core operating performance.

Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under IFRS. Some of these limitations are:

although amortization and depreciation are non-cash charges, the assets being amortized and depreciated may have to be replaced in the future, and adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;adjusted EBITDA does not reflect the potentially dilutive impact of equity-based compensation; andother companies, including our competitors in various industries, may calculate adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.

We define adjusted EBITDA as profit (loss) for the period excluding (i) non-cash items such as depreciation expenses, amortization expenses, stock-based compensation expenses and impairment loss on intangible assets and (ii) extraordinary items associated with one-time events and transactions, such as one-time transaction-related expenses not eligible for capitalization.

Reconciliation of Non-IFRS Financial Measures:

For the year ended December 31,

($ in dollars, unless otherwise stated)

2022

2023

2024

Loss for the year

$

(11,394,768)

$

(1,215,789)

$(84,976,720)

Add (less):

Income tax (benefit) expense

(247,177)

(591,082)

(307,246)

Finance costs

137,029

298,958

8,167,872

Other gains and losses(1)

8,174,802

(5,458,803)

851,689

Other income

(75,576)

(409,555)

(58,024)

Interest Income

(10,994)

(19,340)

(21,773)

Operating loss

$

(3,416,684)

$

(7,395,611)

$(76,344,202)

Add:

Depreciation expenses

433,262

1,025,783

1,139,488

Amortization expenses

1,058,392

1,809,774

2,101,080

Stock-based compensation expense

237,301

118,800

250,952

Impairment loss on intangible assets(2)

298,424

29,026,050

One-time transaction-related expenses(3)

3,144,668

42,972,458

Adjusted EBITDA

(1,687,729)

(998,162)

(854,174)

Adjusted EBITDA Margin (%)

-8.4

%

-2.8

%

-1.8

%

(1)

Other gains and losses for the year ended December 31, 2022 comprise an $8.2 million loss mainly attributed to a change in the fair value through profit and loss (“FVPTL”) associated with our convertible preference shares. Other gains and losses for the year ended December 31, 2023 comprise a $5.5 million gain mainly attributed to a change in the FVPTL associated with the conversion of all of our preference shares into our ordinary shares at a lower fair value during the year ended December 31, 2023. Other gains and losses for the year ended December 31, 2024 comprise a $0.8 million loss mainly attributed to a change in FVTPL associated with the convertible promissory note and warrants.

(2)

For the year ended December 31, 2023, we incurred approximately $0.3 million of impairment loss on intangible assets due to the closure of our e-commerce platform CoSTORY as the internally-developed software on which CoSTORY relied became no longer recoverable. For the year ended December 31, 2024, we incurred impairment loss on intangible assets of approximately $29.0 million, which mainly consisted of (i) an impairment loss of $25.5 million against the goodwill of Mediagene recognized because, following the merger with Mediagene in May 2023 and during subsequent operations in 2024, it became evident that the anticipated synergies fell short of initial expectations due to changes in the overall environment, necessitating adjustments to the financial projections and, as a result of this downward revision in projected future revenues, the fair value declined, leading to the recognition of an impairment loss and (ii) an impairment loss of $3.1 million due to the downsizing of the e-commerce department of Polydice Inc. 

(3)

For the year ended December 31, 2023, one-time transaction-related expenses comprise the professional service fees related to (i) the merger with Mediagene; and (ii) preparation for our merger (the “Merger”) with Blue Ocean Acquisition Corporation (“Blue Ocean”) and the listing on the Nasdaq, which were not eligible for capitalization. For the year ended December 31, 2024, one-time transaction-related expenses comprise (i) the professional service fees related to the closing of the Merger and listing on the Nasdaq of $4.3 million; (ii) the professional service fees related to the acquisition of Green Quest Holdings, Inc. of $0.5 million; and (iii) the listing expense of $38.2 million from the excess of the fair value of TNL Mediagene Ordinary Shares issued over the fair value of Blue Ocean’s identifiable net assets on the Closing Date of the Merger, each of which was not eligible for capitalization.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tnl-mediagene-pursues-cost-efficient-expansion-with-new-c-level-hires-and-strategic-ma-focus-302448766.html

SOURCE TNL Mediagene

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

BlueNexus Technologies Unveils AquaX Hub at SIWW 2026 — AI Autonomous Operations Extended to Legacy Water Assets

Published

on

By

SINGAPORE, June 21, 2026 /PRNewswire/ — At Singapore International Water Week (SIWW) 2026, BlueNexus Technologies unveiled the global debut of AquaX Hub™ — a compact plug-and-play edge device that brings full AI-powered autonomous operation to standalone water equipment and legacy treatment plants. The launch drew sustained engagement from utilities, industrial operators and engineering firms.

The water sector confronts converging pressures: aging infrastructure, a critical shortage of skilled technicians, and relentless operational cost escalation. AquaX Hub™ answers these directly — extending the AI autonomous operation already proven plant-wide by AquaX Robot™ to a single asset, and delivering comparable monitoring and operational management without a control-system overhaul.

“The industry cannot hire its way out of this problem,” said Jack Zhang, CEO of BlueNexus Technologies. “AI autonomous operation is no longer a future concept — the barrier to entry is gone.”

The AquaX Ecosystem

BlueNexus has built the industry’s first fully integrated AI autonomous water operation platform, spanning three complementary pillars:

AquaX Robot™ is the flagship plant-wide AI agent, built on large language models with proprietary vision, acoustic and infrared multimodal sensing. It optimizes treatment processes 24/7 and predicts equipment failures. Live deployments show up to 90% reduction in on-site staffing, a 50% drop in equipment breakdowns, and approximately 35% lower O&M costs.

AquaX Hub™, making its global debut at SIWW 2026, is a lightweight edge terminal extending that capability to any water system. With an independent local processing module, it monitors and inspects equipment through multimodal sensing and runs a self-contained processing loop. The device integrates seamlessly with existing SCADA, cloud and enterprise platforms via standardized APIs.

i-WaterHub™, the company’s standardized modular treatment plant, operated autonomously by AquaX Robot, delivers 2,500 to 40,000 m³/day for municipal and industrial applications.

Market Momentum

SIWW 2026 convened nearly 500 exhibitors from over 65 countries. BlueNexus has identified priority markets for AquaX Hub™ in Southeast Asia, the Middle East and Africa. “The conversations this week have already translated into concrete business opportunities and we expect rapid deployment in the coming months.” Zhang confirmed.

About BlueNexus Technologies

BlueNexus Technologies is a Singapore-based water-technology company building intelligent, AI-operated systems for the world’s most water-intensive industries. We design and deliver modular water treatment infrastructure that is smarter to run, faster to deploy, and built to operate autonomously.

Web: www.bluenexus.tech

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/bluenexus-technologies-unveils-aquax-hub-at-siww-2026–ai-autonomous-operations-extended-to-legacy-water-assets-302805849.html

SOURCE BlueNexus Technologies

Continue Reading

Technology

VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS

Published

on

By

With the presence of Emmanuel Macron and Narendra Modi, Prime Minister of India

PARIS, June 20, 2026 /CNW/ — From June 17 to 20, 2026 at Paris Porte de Versailles, VivaTech celebrated its 10th edition, surpassing the exceptional milestone of 200,000 visitors from 165 nationalities, with more than 15,000 startups present, 1,155 speakers and over 5 billion cumulative impressions on social media. Europe’s largest tech and innovation event has reached a new dimension, consolidating its status as an unmissable global gathering.

Exceptional speakers

VivaTech welcomed the greatest figures in global tech: Jeff Bezos (Amazon & Blue Origin), Dave Limp (Blue Origin), Bernard Arnault (LVMH), Henna Virkkunen (European Commission), Ekaterina Zaharieva (European Commission). Germany, Country of the Year 2026, was represented by a ministerial delegation, while India, AI Country Partner 2026, was led by Prime Minister Narendra Modi, as a continuation of the AI Summit in New Delhi.

Innovation and business at the heart of the event

More than 4,500 exhibitors, 61% of whom were international, showcased their latest innovations. Among the standout innovations: the smart contact lens by XPANCEO, the thought-controlled humanoid robot by Unitree x HABS, and the 3D-printed resorbable implants by Lattice Medical. New formats such as the Business Plaza and Investors Office Hours further accelerated business connections.

The VivaTech x Bloomberg Awards

For the first time, VivaTech presented the VivaTech x Bloomberg Awards, recognising the most influential figures in global tech, including Sir Tim Berners-Lee (Visionary Award), Joe Tsai (Leadership Award) and Yann LeCun (Momentum Award).

Innovation open to all

VivaTech also took over the Champs-Élysées on June 14th for an open-air technology showcase, before opening its doors to the general public on June 20th with astronaut Thomas Pesquet as guest star.

“This 10th edition was not a celebration of the 9 previous years, but the opening of a new decade full of promise.” — Maurice Lévy, Michèle Benbunan & François Bitouzet, VivaTech

See you from June 16 to 19, 2027 at Paris Expo Porte de Versailles for VivaTech 2027!

About VivaTech

VivaTech accelerates innovation by connecting startups, tech leaders, major companies, and investors responding to our world’s biggest challenges.  

Each year, over four exciting days in Paris, VivaTech creates Europe’s biggest startup and tech event, exploring the most disruptive topics in tech with world-premiere demos, launches, and conferences in a collaborative ecosystem. This is where business meets innovation. Join us for the eleventh edition of VivaTech 16-19 June 2027.

For more information go to our website at https://vivatech.com/media or follow us on social media @VivaTech.

Contact
press@vivatechnology.com 

Logo: https://mmx.prnewswire.com/media/MS1865564/VT_LOGO_EN.jpg
Photo : https://mmx.prnewswire.com/media/MS1869778/VivaTech_2026.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/vivatech-2026-celebrates-its-10th-anniversary-with-a-record-edition-surpassing-200-000-visitors-302805827.html

SOURCE VivaTech

Continue Reading

Technology

Pope Leo XIV embraces paediatric patients at CNAO in Pavia

Published

on

By

PAVIA, Italy, June 20, 2026 /PRNewswire/ — The National Center for Oncological Hadrontherapy (CNAO) served as the first stop today during Pope Leo XIV’s pastoral visit to the city of Pavia. His choice to begin his journey at this center reflects a profound commitment to fostering meaningful dialogue between advanced scientific progress and the alleviation of human suffering.

CNAO President Gianluca Vago and General Manager Sandro Rossi received His Holiness, illustrating the center’s distinctive capabilities. CNAO stands out as a unique reality in Italy, remaining one of the very few facilities worldwide capable of delivering hadrontherapy using both protons and carbon ions. The technological core of the facility is its synchrotron, a subatomic particle accelerator that generates ultra-high-precision beams to treat complex, inoperable and radioresistant tumours. This cutting-edge technology allows for the targeted eradication of diseased cells while meticulously preserving surrounding healthy tissues, drastically improving patients’ survival and quality of life.

Furthermore, CNAO is expanding its capabilities as a premier multi-center utilizing new ion species, like Helium, later Oxygen and Neon. Soon, treatments will incorporate the Leo Cancer Care upright positioning and imaging system. The immediate future also includes beginning therapies with a Hitachi dedicated proton accelerator and gantry and a BNCT system for metastatic diseases, equipped with an electrostatic accelerator produced by TAE Life Science. With these new technologies, CNAO will become one of the most technologically advanced center in the world.

To date, over six thousand individuals, including approximately three hundred children and adolescents, have benefited from these life-saving treatments.

During his visit, the Pope engaged with CNAO’s Board of Directors, a collaborative body uniting national universities, clinical institutions, and research centers. He also extended his heartfelt greetings to the two hundred employees of the center. These doctors, physicists, engineers, and researchers tirelessly operate the advanced technologies in the service of oncology patients.

The emotional pinnacle of the day was the Holy Father’s private gathering with a delegation of young children who underwent treatment. The paediatric patients and their families shared a deeply touching moment of closeness, receiving the Pope’s comforting embrace.

“The visit of Pope Leo XIV honours us and represents a moment of extraordinary human value”, stated CNAO President Gianluca Vago. “In his encyclical Magnifica Humanitas, the Holy Father emphasizes the necessity of a science that constantly safeguards the centrality of the person and directs technology toward the common good. In a time marked by global tensions, CNAO testifies daily how the incredible power of the atom can be used not to destroy, but to heal. The particle beams we utilize against disease are, symbolically, Rays of Hope, sharing and supporting the IAEA project bearing this name. The embrace the Holy Father reserved for our children reminds us that scientific research finds its most authentic purpose when it encounters listening, compassion, and hope”.

Photo – https://mma.prnewswire.com/media/2997869/Papa_al_Cnao_crediti_Andrea_Perotti.jpg
Logo – https://mma.prnewswire.com/media/2997643/CNAO_Logo.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/pope-leo-xiv-embraces-paediatric-patients-at-cnao-in-pavia-302805799.html

Continue Reading

Trending